Presentation is loading. Please wait.

Presentation is loading. Please wait.

Why we should ‘shock and kill’

Published byθάνα Αποστολίδης Modified over 6 years ago

Similar presentations

Presentation on theme: "Why we should ‘shock and kill’"— Presentation transcript:

1 Why we should ‘shock and kill’
Professor Sharon R Lewin, FRACP, PhD, FAHMS Director, Doherty Institute, The University of Melbourne and Royal Melbourne Hospital IAS Community Workshop of HIV Cure, Amsterdam, July 2018

2 Some definitions Shock and kill Block and lock

3 Eliminate viral rebound off ART
The overall goal Safe Time limited Cheap Accessible Effective in all clades Eliminate viral rebound off ART through Reducing the replication competent reservoir

4 Shock and kill: a two step strategy
Immune mediated killing or Pro-apoptotic drugs Shock Latency reversing agent Productive infection Cell death Latent infection

5 We have many drugs that can ‘shock’
None are HIV specific None are as potent as T-cell activation Unclear if virus is coming from all cells or just a few Still need better LRAs dCA Kim, Anderson and Lewin. Cell Host Microbe 2018

6 What about the kill? Vaccines Immune check point blockade CAR T-cells
Antibodies BITEs DARTs bNAbs

7 What happens when we combine shock + kill?
Romedepsin Vacc 4x REDUC Lancet HIV N=17 = + No change in DNA shock kill Romedespin ChAd/MVA BCN02 CROI2018 N=15 + = Viral rebound (half) Vorinostat ChAd/MVA HIVcons RIVER AIDS 2018 N=60 = No change in DNA + TLR7 PGT121 bNAB + = REMISSION (50%) monkeys

8 Kill compounds Shock + HIV proteins/RNA Latent infection Cell death
OX40/SIRC Kuo, Immunity 2018 Cummins J Virol 2016 Wong Nat Med 2016 Cummins AIDS 2018 Kim AIDS2018 Munoz-Arias AIDS2018 survival Cell death

9 What are the challenges for shock and kill?
Need more potent, less toxic and more specific agents that shock. Combinations of shock agents coming Unclear if targeting all infected cells will be possible, especially tissue Could activating virus have adverse effects on immune activation, brain reservoirs? No evidence in 10+ trials Immune escape might be a problem for immune mediated killing but not kill compounds This is just about reducing the reservoir - will still need long term immune control

10 What will be better? Safe Time limited Cheap Accessible
Shock and kill Block and lock Safe Time limited Cheap Accessible Effective in all clades Induce remission off ART

Download ppt "Why we should ‘shock and kill’"

Similar presentations

+ Viruses and Prions. + What is a virus? DNA enclosed in a protein shell They are not alive Need cells to survive.

+ Viruses and Prions. + What is a virus? DNA enclosed in a protein shell They are not alive Need cells to survive.
Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.

Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.
New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.

New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway

Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Measuring the latent HIV Reservoir

Measuring the latent HIV Reservoir
Www.aids2014.org The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays Ole Schmeltz.

The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays Ole Schmeltz.
Short video on patients’ perspectives on cure

Short video on patients’ perspectives on cure
Latency reversing agents

Latency reversing agents
1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8): 607-614.

1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):
Strategies for Targeting and Eradicating the HIV Reservoir

Strategies for Targeting and Eradicating the HIV Reservoir
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.

David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
How HIV affects the Immune System. INTRODUCTION HIV attacks and kills crucial immune system cells, known as T-helper cells. Without T-helper cells many.

How HIV affects the Immune System. INTRODUCTION HIV attacks and kills crucial immune system cells, known as T-helper cells. Without T-helper cells many.
Estrogen blocks HIV re-emergence from latency and points to gender- specific differences in HIV reservoirs Jonathan Karn International AIDS Society Hammer.

Estrogen blocks HIV re-emergence from latency and points to gender- specific differences in HIV reservoirs Jonathan Karn International AIDS Society Hammer.
IAS 2012 feedback: www.i-Base.info UK Consortium: September 2012 IAS 2012 Feedback: New findings, better drugs and the goal of a cure Simon Collins HIV.

IAS 2012 feedback: UK Consortium: September 2012 IAS 2012 Feedback: New findings, better drugs and the goal of a cure Simon Collins HIV.
Future directions in HIV basic science research The hunt for a cure.

Future directions in HIV basic science research The hunt for a cure.
+ Viruses and Prions. + What is a virus? DNA enclosed in a protein shell They are not alive Need cells to survive.

+ Viruses and Prions. + What is a virus? DNA enclosed in a protein shell They are not alive Need cells to survive.
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,

Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.

Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Are we most likely to cure HIV with gene therapy? Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,

Are we most likely to cure HIV with gene therapy? Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,
Myeloid dendritic cells induce HIV-1 latency in non- proliferating CD4 + T cells IAS WORKSHOP, 16 & 17 JULY 2010.

Myeloid dendritic cells induce HIV-1 latency in non- proliferating CD4 + T cells IAS WORKSHOP, 16 & 17 JULY 2010.

Similar presentations

Ads by Google